Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03747042 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
A Phase 2 study of Breast Cancer Female, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT03747042 is a Phase 2 study of Breast Cancer Female that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 61 participants, below the 691-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03747042, a Phase 2 study of Breast Cancer Female, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy for tissue acquisition, study participants will take a 7- to 30-day (1-4 weeks) course of letrozole in accordance with standard of care. They will then undergo definitive surgical resection of their primary tumor (mastectomy vs lumpectomy) as per standard of care guidelines.
Conditions Studied
Interventions
- DRUG Letrozole
Study Locations (1)
Texas
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03747042
The ClinicalTrials.gov registry entry for NCT03747042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 691-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (91% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Letrozole is the first listed.
NCT03747042 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03747042 about?
NCT03747042 is a clinical study titled "Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer". A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers. After undergoing a core needle biopsy for tissue acquisition, study participants will take a 7- to 30-day (1-4 weeks) course of letrozole in accordance with stan...
What is the current status of trial NCT03747042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2018-11-27. Estimated completion is 2025-02-24.
What conditions does trial NCT03747042 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT03747042?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT03747042?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03747042 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Microbiome and Association With Implant Infections
RECRUITING · Phase 2
-
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RECRUITING · Phase 2
-
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
RECRUITING · Phase 2
-
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.